Harvard Bioscience (HBIO) Equity Average (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Equity Average data on file, last reported at $11.9 million in Q1 2026.

• Quarterly Equity Average fell 69.58% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (down 69.58% YoY) and the FY2025 annual result came in at $38.5 million, down 43.5% from the prior year.
• Equity Average slipped to $11.9 million in Q1 2026 per HBIO's latest filing, from $13.9 million in the prior quarter.
• Across five years, Equity Average topped out at $79.9 million in Q1 2022 and bottomed at $11.9 million in Q1 2026.
• The 5-year median for Equity Average is $70.9 million (2024), against an average of $56.8 million.
• The widest annual swing landed in 2022, when Equity Average advanced 3.89%; it then tumbled 78.39% in 2025.
• Tracing HBIO's Equity Average over 5 years: stood at $72.1 million in 2022, then grew by 2.19% to $73.7 million in 2023, then fell by 12.69% to $64.3 million in 2024, then plunged by 78.39% to $13.9 million in 2025, then fell by 14.47% to $11.9 million in 2026.
• Per Business Quant, the three latest HBIO Equity Average figures stand at $11.9 million (Q1 2026), $13.9 million (Q4 2025), and $14.9 million (Q3 2025).

Peer Comparison